AVDL - Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results | Benzinga
Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.
Avadel Pharmaceuticals posted a quarterly loss of 32 cents per share, compared to market expectations for a loss of 29 cents per share. The company’s quarterly sales came in at $19.45 million versus estimates of $18.11 million, according to data from Benzinga Pro.
"We are carrying significant momentum into 2024 following the successful launch of LUMRYZ and are pleased with the strong early launch results we have seen. We have established a strong foundation with patients, ...